Last 12 months
Inside the activity.
0 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 22, 2022 Filed Jun 23, 2022 16:15 UTC |
DOWNEY BRUCEDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038861 · doc4.xml · derivative · entry 1 DOWNEY BRUCE · CIK 0001237257 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:16 UTC |
Dubin GlennDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038864 · doc4.xml · derivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 20:16 UTC |
Anderson Kenneth CarlDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $6.06 | $0.00 |
DisclosureSEC source: 0001209191-22-038865 · doc4.xml · derivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2032-06-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 22, 2023 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 16:45 UTC Amendment |
Boyle Scott NChief Business Officer
|
Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036711 · doc4a.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment |
White LaurenChief Financial Officer
|
Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036714 · doc4a.xml · nonDerivative · entry 1 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment |
Hirsch AndrewDirector · President & CEO
|
Tax withholdingCommon Stock | 3,675 | $7.01 | $25,761.75 |
DisclosureSEC source: 0001209191-22-036716 · doc4a.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,825 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment |
Siegel JolieChief Legal Officer
|
Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036718 · doc4a.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment |
Fisher StewartChief Scientific Officer
|
Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036715 · doc4a.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,038 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment |
Schick KellyChief People Officer
|
Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036713 · doc4a.xml · nonDerivative · entry 1 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 26, 2022 Filed Jun 14, 2022 20:45 UTC Amendment |
Crystal AdamChief Medical Officer
|
Tax withholdingCommon Stock | 1,102 | $7.01 | $7,725.02 |
DisclosureSEC source: 0001209191-22-036712 · doc4a.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,648 F1 · kind: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of performance restricted stock units and does not represent a sale by the Reporting Person. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:15 UTC |
Boyle Scott NChief Business Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032510 · doc4.xml · derivative · entry 2 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:15 UTC |
Boyle Scott NChief Business Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032510 · doc4.xml · nonDerivative · entry 1 Boyle Scott N · CIK 0001913897 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC |
White LaurenChief Financial Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032509 · doc4.xml · derivative · entry 2 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC |
White LaurenChief Financial Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032509 · doc4.xml · nonDerivative · entry 1 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC |
Hirsch AndrewDirector · President & CEO
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032508 · doc4.xml · derivative · entry 2 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 12,500 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC |
Hirsch AndrewDirector · President & CEO
|
Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032508 · doc4.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC |
Siegel JolieChief Legal Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032515 · doc4.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC |
Siegel JolieChief Legal Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032515 · doc4.xml · nonDerivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC |
Crystal AdamChief Medical Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032514 · doc4.xml · derivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC |
Crystal AdamChief Medical Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032514 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC |
Schick KellyChief People Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032512 · doc4.xml · derivative · entry 2 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:16 UTC |
Schick KellyChief People Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032512 · doc4.xml · nonDerivative · entry 1 Schick Kelly · CIK 0001797388 · Chief People Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionPerformance Restricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032511 · doc4.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 3,750 shares Expires 2025-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:15 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-032511 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| April 12, 2022 Filed Apr 12, 2022 20:05 UTC |
Hirsch AndrewDirector · President & CEO
|
PurchaseCommon Stock | 10,000 | $8.40 | $84,000.00 |
DisclosureSEC source: 0001209191-22-024130 · doc4.xml · nonDerivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,928 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · derivative · entry 4 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,152 Underlying: Common Stock · 25,928 shares Expires 2030-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests and becomes exercisable in 20 equal quarterly installments, with the first installment vested on September 5, 2020. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,156 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · derivative · entry 3 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,572 Underlying: Common Stock · 2,156 shares Expires 2028-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 20% of this option vested and became exercisable on May 1, 2019, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionCommon Stock | 25,928 | $4.98 | $129,121.44 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · nonDerivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2022 Filed Apr 13, 2022 00:41 UTC |
Fisher StewartChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,156 | $3.71 | $7,998.76 |
DisclosureSEC source: 0001209191-22-024228 · doc4.xml · nonDerivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 16:26 UTC |
COHEN ALAIN JDirector
|
GrantCommon Stock | 388 | $26.46 | $10,266.48 |
DisclosureSEC source: 0001209191-22-023018 · doc4.xml · nonDerivative · entry 1 COHEN ALAIN J · CIK 0001132946 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 928 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 16:27 UTC |
Dubin GlennDirector
|
GrantCommon Stock | 379 | $26.46 | $10,028.34 |
DisclosureSEC source: 0001209191-22-023021 · doc4.xml · nonDerivative · entry 1 Dubin Glenn · CIK 0001308597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 873 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:25 UTC |
Anderson Kenneth CarlDirector
|
GrantCommon Stock | 341 | $26.46 | $9,022.86 |
DisclosureSEC source: 0001209191-22-023016 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,316 F1 · kind: These shares were issued in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on April 4, 2022. Read SEC document |
| March 16, 2022 Filed Mar 17, 2022 20:20 UTC |
Koppikar UtpalDirector
|
GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $22.64 | $0.00 |
DisclosureSEC source: 0001209191-22-019573 · doc4.xml · derivative · entry 1 Koppikar Utpal · CIK 0001742696 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2032-03-15 F1 · derivative.exercise_date: 33% of the shares underlying this option shall vest and become exercisable on March 16, 2023, with the remainder vesting in eight equal quarterly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 23, 2022 21:30 UTC |
Hirsch AndrewDirector · President & CEO
|
GrantPerformance Restricted Stock Units · Derivative | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-012216 · doc4.xml · derivative · entry 1 Hirsch Andrew · CIK 0001586707 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 87,500 shares Expires 2025-02-28 F1 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F1 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 72,500 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
White LaurenChief Financial Officer
|
GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010206 · doc4.xml · derivative · entry 2 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
White LaurenChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010206 · doc4.xml · derivative · entry 1 White Lauren · CIK 0001864430 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
Fisher StewartChief Scientific Officer
|
GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010208 · doc4.xml · derivative · entry 2 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
Fisher StewartChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010208 · doc4.xml · derivative · entry 1 Fisher Stewart · CIK 0001824863 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
Crystal AdamChief Medical Officer
|
GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010204 · doc4.xml · derivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
Crystal AdamChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 118,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010204 · doc4.xml · derivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
Siegel JolieChief Legal Officer
|
GrantPerformance Restricted Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-010207 · doc4.xml · derivative · entry 2 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,250 Underlying: Common Stock · 26,250 shares Expires 2025-02-28 F2 · derivative.exercise_price: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. F2 · derivative.exercise_date: Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 21:30 UTC |
Siegel JolieChief Legal Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $22.71 | $0.00 |
DisclosureSEC source: 0001209191-22-010207 · doc4.xml · derivative · entry 1 Siegel Jolie · CIK 0001768223 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-13 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,334 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · derivative · entry 9 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,668 Underlying: Common Stock · 1,334 shares Expires 2030-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares underlying this option vest and become exercisable in 12 equal quarterly installments, with the first installment vested on October 1, 2020. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 803 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · derivative · entry 8 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,137 Underlying: Common Stock · 803 shares Expires 2026-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 12.5% of the shares underlying this option vested and became exercisable on December 31, 2016, with the remainder vesting in 28 equal quarterly installments thereafter. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 1,334 | $4.98 | $6,643.32 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · nonDerivative · entry 2 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,975 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2022 Filed Jan 26, 2022 22:26 UTC |
Anderson Kenneth CarlDirector
|
Exercise / conversionCommon Stock | 803 | $2.11 | $1,694.33 |
DisclosureSEC source: 0001209191-22-005107 · doc4.xml · nonDerivative · entry 1 Anderson Kenneth Carl · CIK 0001824862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC |
Crystal AdamChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · derivative · entry 4 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,292 Underlying: Common Stock · 15,000 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F4 · derivative.exercise_date: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC |
Crystal AdamChief Medical Officer
|
SaleCommon Stock | 1,054 | $32.66 | $34,420.48 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · nonDerivative · entry 3 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.32 to $33.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC |
Crystal AdamChief Medical Officer
|
SaleCommon Stock | 13,946 | $31.59 | $440,547.17 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · nonDerivative · entry 2 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,054 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.00 to $31.90. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| January 04, 2022 Filed Jan 5, 2022 21:30 UTC |
Crystal AdamChief Medical Officer
|
Exercise / conversionCommon Stock | 15,000 | $6.49 | $97,350.00 |
DisclosureSEC source: 0001209191-22-001700 · doc4.xml · nonDerivative · entry 1 Crystal Adam · CIK 0001825445 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.